Added Value of Estrogen Receptor, Progesterone Receptor, and L1
Cell Adhesion Molecule Expression to Histology-Based
Endometrial Carcinoma Recurrence Prediction Models: An ENITEC
Collaboration Study

J 2018

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

PUTTEN, Louis J. van der, Nicole C. M. VISSER, Ko van de VIJVER, Maria SANTACANA, Peter BRONSERT et. al.

Basic information

Original name

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

Authors

PUTTEN, Louis J. van der (528 Netherlands, guarantor), Nicole C. M. VISSER (528 Netherlands), Ko van de VIJVER (528 Netherlands), Maria SANTACANA (724 Spain), Peter BRONSERT (276 Germany), Johan BULTEN (528 Netherlands), Marc HIRSCHFELD (276 Germany), Eva COLAS (724 Spain), Antonio GIL-MORENO (724 Spain), Angel GARCIA (724 Spain), Gemma MANCEBO (724 Spain), Fransesca ALAMEDA (724 Spain), Jone TROVIK (578 Norway), Reidun K. KOPPERUD (578 Norway), Jutta HUVILA (246 Finland), Stefanie SCHRAUWEN (56 Belgium), Martin KOSKAS (250 France), Francine WALKER (250 France), Vít WEINBERGER (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Eva JANDÁKOVÁ (203 Czech Republic), Marc P. L. M. SNIJDERS (528 Netherlands), Sa VAN DEN BERG-VAN ERP (528 Netherlands), Xavier MATIAS-GUIU (724 Spain), Helga B. SALVESEN (578 Norway), Henrica M. J. WERNER (578 Norway), Frederic AMANT (56 Belgium), Leon F. A. G. MASSUGER (528 Netherlands) and Johanna M. A. PIJNENBORG (528 Netherlands)

Edition

International Journal of Gynecological Cancer, Philadelphia, Lippincott Williams & Wilkins, 2018, 1048-891X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.746

RIV identification code

RIV/00216224:14110/18:00104087

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1097/IGC.0000000000001187

UT WoS

000426550300015

Keywords in English

Endometrial carcinoma; Endometrioid; Nonendometrioid; Estrogen receptor; Progesteron receptor; L1CAM; Prognosis; Immunohistochemistry

Abstract

V originále

Objectives Endometrial carcinoma mortality is mainly caused by recurrent disease, and various immunohistochemical markers to predict recurrences have been studied. Loss of the estrogen receptor (ER) and progesterone receptor (PR) and the presence of the L1 cell adhesion molecule (L1CAM) are promising markers, but their combined value has not been studied. Materials and Methods Expression of ER, PR, and L1CAM was immunohistochemically determined in 293 endometrial carcinomas from 11 collaborating European Network for Individualized Treatment of Endometrial Cancer centers. Estrogen receptor, PR, or L1CAM staining was considered positive or negative when expressed by greater than or equal to 10% or less than 10% of the tumor cells, respectively. The association between these markers and clinicopathological markers, and their combined value in predicting survival were calculated, both in the entire cohort and in a selected groups of stage I endometrioid and low-risk stage I endometrioid carcinomas. Results Estrogen receptor and PR were negative in 19% and 28% of the cases, respectively, and L1CAM was positive in 18%. All 3 were associated with advanced stage, high-grade, nonendometrioid histology, lymphovascular space invasion (LVSI), and reduced disease-free survival. Only advanced stage, loss of PR, and LVSI were associated with reduced disease-free survival in multivariate analysis. A prognostic model including these 3 markers was superior to 1 including only the 3 immunohistochemical markers, which was superior to the traditional model. In both the stage I endometrioid and the low-risk stage I endometrioid groups, only loss of PR was associated with reduced disease-free survival. Conclusions Loss of ER and PR, and the presence of L1CAM are associated with high risk characteristics, and loss of PR is the strongest predictor of recurrent disease. Although a combination of these 3 markers is slightly superior to the traditional histological markers, a prognostic model including stage, PR expression, and LVSI is the most promising model in the identification of high risk carcinomas. In the stage I endometrioid carcinomas, PR immunohistochemistry appears to be of additional value in predicting recurrences.

Citovat

PUTTEN, Louis J. van der, Nicole C. M. VISSER, Ko van de VIJVER, Maria SANTACANA, Peter BRONSERT, Johan BULTEN, Marc HIRSCHFELD, Eva COLAS, Antonio GIL-MORENO, Angel GARCIA, Gemma MANCEBO, Fransesca ALAMEDA, Jone TROVIK, Reidun K. KOPPERUD, Jutta HUVILA, Stefanie SCHRAUWEN, Martin KOSKAS, Francine WALKER, Vít WEINBERGER, Luboš MINÁŘ, Eva JANDÁKOVÁ, Marc P. L. M. SNIJDERS, Sa VAN DEN BERG-VAN ERP, Xavier MATIAS-GUIU, Helga B. SALVESEN, Henrica M. J. WERNER, Frederic AMANT, Leon F. A. G. MASSUGER and Johanna M. A. PIJNENBORG. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, 2018, vol. 28, No 3, p. 514-523. ISSN 1048-891X. Available from: https://dx.doi.org/10.1097/IGC.0000000000001187.

@article{1451456,
   author = {Putten, Louis J. van der and Visser, Nicole C. M. and Vijver, Ko van de and Santacana, Maria and Bronsert, Peter and Bulten, Johan and Hirschfeld, Marc and Colas, Eva and GilandMoreno, Antonio and Garcia, Angel and Mancebo, Gemma and Alameda, Fransesca and Trovik, Jone and Kopperud, Reidun K. and Huvila, Jutta and Schrauwen, Stefanie and Koskas, Martin and Walker, Francine and Weinberger, Vít and Minář, Luboš and Jandáková, Eva and Snijders, Marc P. L. M. and van den Bergandvan Erp, Sa and MatiasandGuiu, Xavier and Salvesen, Helga B. and Werner, Henrica M. J. and Amant, Frederic and Massuger, Leon F. A. G. and Pijnenborg, Johanna M. A.},
   article_location = {Philadelphia},
   article_number = {3},
   doi = {http://dx.doi.org/10.1097/IGC.0000000000001187},
   keywords = {Endometrial carcinoma; Endometrioid; Nonendometrioid; Estrogen receptor; Progesteron receptor; L1CAM; Prognosis; Immunohistochemistry},
   language = {eng},
   issn = {1048-891X},
   journal = {International Journal of Gynecological Cancer},
   title = {Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study},
   volume = {28},
   year = {2018}
}

TY  - JOUR
ID  - 1451456
AU  - Putten, Louis J. van der - Visser, Nicole C. M. - Vijver, Ko van de - Santacana, Maria - Bronsert, Peter - Bulten, Johan - Hirschfeld, Marc - Colas, Eva - Gil-Moreno, Antonio - Garcia, Angel - Mancebo, Gemma - Alameda, Fransesca - Trovik, Jone - Kopperud, Reidun K. - Huvila, Jutta - Schrauwen, Stefanie - Koskas, Martin - Walker, Francine - Weinberger, Vít - Minář, Luboš - Jandáková, Eva - Snijders, Marc P. L. M. - van den Berg-van Erp, Sa - Matias-Guiu, Xavier - Salvesen, Helga B. - Werner, Henrica M. J. - Amant, Frederic - Massuger, Leon F. A. G. - Pijnenborg, Johanna M. A.
PY  - 2018
TI  - Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study
JF  - International Journal of Gynecological Cancer
VL  - 28
IS  - 3
SP  - 514-523
EP  - 514-523
PB  - Lippincott Williams & Wilkins
SN  - 1048891X
KW  - Endometrial carcinoma
KW  - Endometrioid
KW  - Nonendometrioid
KW  - Estrogen receptor
KW  - Progesteron receptor
KW  - L1CAM
KW  - Prognosis
KW  - Immunohistochemistry
N2  - Objectives Endometrial carcinoma mortality is mainly caused by recurrent disease, and various immunohistochemical markers to predict recurrences have been studied. Loss of the estrogen receptor (ER) and progesterone receptor (PR) and the presence of the L1 cell adhesion molecule (L1CAM) are promising markers, but their combined value has not been studied. Materials and Methods Expression of ER, PR, and L1CAM was immunohistochemically determined in 293 endometrial carcinomas from 11 collaborating European Network for Individualized Treatment of Endometrial Cancer centers. Estrogen receptor, PR, or L1CAM staining was considered positive or negative when expressed by greater than or equal to 10% or less than 10% of the tumor cells, respectively. The association between these markers and clinicopathological markers, and their combined value in predicting survival were calculated, both in the entire cohort and in a selected groups of stage I endometrioid and low-risk stage I endometrioid carcinomas. Results Estrogen receptor and PR were negative in 19% and 28% of the cases, respectively, and L1CAM was positive in 18%. All 3 were associated with advanced stage, high-grade, nonendometrioid histology, lymphovascular space invasion (LVSI), and reduced disease-free survival. Only advanced stage, loss of PR, and LVSI were associated with reduced disease-free survival in multivariate analysis. A prognostic model including these 3 markers was superior to 1 including only the 3 immunohistochemical markers, which was superior to the traditional model. In both the stage I endometrioid and the low-risk stage I endometrioid groups, only loss of PR was associated with reduced disease-free survival. Conclusions Loss of ER and PR, and the presence of L1CAM are associated with high risk characteristics, and loss of PR is the strongest predictor of recurrent disease. Although a combination of these 3 markers is slightly superior to the traditional histological markers, a prognostic model including stage, PR expression, and LVSI is the most promising model in the identification of high risk carcinomas. In the stage I endometrioid carcinomas, PR immunohistochemistry appears to be of additional value in predicting recurrences.
ER  -

PUTTEN, Louis J. van der, Nicole C. M. VISSER, Ko van de VIJVER, Maria SANTACANA, Peter BRONSERT, Johan BULTEN, Marc HIRSCHFELD, Eva COLAS, Antonio GIL-MORENO, Angel GARCIA, Gemma MANCEBO, Fransesca ALAMEDA, Jone TROVIK, Reidun K. KOPPERUD, Jutta HUVILA, Stefanie SCHRAUWEN, Martin KOSKAS, Francine WALKER, Vít WEINBERGER, Luboš MINÁŘ, Eva JANDÁKOVÁ, Marc P. L. M. SNIJDERS, Sa VAN DEN BERG-VAN ERP, Xavier MATIAS-GUIU, Helga B. SALVESEN, Henrica M. J. WERNER, Frederic AMANT, Leon F. A. G. MASSUGER and Johanna M. A. PIJNENBORG. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. \textit{International Journal of Gynecological Cancer}. Philadelphia: Lippincott Williams \&{} Wilkins, 2018, vol.~28, No~3, p.~514-523. ISSN~1048-891X. Available from: https://dx.doi.org/10.1097/IGC.0000000000001187.

Detailed Information on Publication Record